Benefit of Bevacizumab in Glioblastoma Under Discussion

This past year, ABC2 called upon the FDA, Genentech and the NCI’s Radiation Therapy Oncology Group, to harmonize the data generated in the various Avastin trials. 

Coordination between the groups would provide better data for the FDA as it considers final approval for the use of Avastin in treating GBM.  It would also provide better information for patients and physicians regarding the risks and benefits of using Avastin to treat GBM. 

This topic continues to draw a lot of attention in the field. 

Click HERE to read a recent article from Medscape discussing an article released in the February 20 issue of the New England Journal of Medicine on this topic.  ABC2’s petitioning of the FDA is noted.

 

 

 

Share |
December 4, 2014 02:02 PM
Concert proceeds benefit Accelerate Brain Cancer Cure.
November 24, 2014 04:43 PM
ABC2-funded research in the news and a blog post by Al Musella, of the Musella Foundation, about Novocure's promising Optune trial results.
November 18, 2014 12:33 PM
Accelerate Brain Cancer Cure funded Duke University's early work on the vaccine.

Join us in our fight for a cure!